CD4 and primary cutaneous T-cell non-Hodgkin lymphoma: This interaction is prevented by Zanolinumab, a human IgG1κ which binds to CD4, leading to inactivation and even apoptosis of CD4 + T-cells -particularly the CD45RA + ones- which are present in most of the cases of CTCL.